WO2005120643A2 - Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms - Google Patents

Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms Download PDF

Info

Publication number
WO2005120643A2
WO2005120643A2 PCT/IT2005/000320 IT2005000320W WO2005120643A2 WO 2005120643 A2 WO2005120643 A2 WO 2005120643A2 IT 2005000320 W IT2005000320 W IT 2005000320W WO 2005120643 A2 WO2005120643 A2 WO 2005120643A2
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
butoxyiminomethylcamptothecin
neoplasm
uterine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2005/000320
Other languages
English (en)
French (fr)
Other versions
WO2005120643A8 (en
WO2005120643A3 (en
Inventor
Paolo Carminati
Marco Corsi
Claudio Zanna
Franco Cavalli
Luca Gianni
Cristiana Sessa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL05761294T priority Critical patent/PL1773451T3/pl
Priority to AU2005251573A priority patent/AU2005251573B2/en
Priority to AT05761294T priority patent/ATE521351T1/de
Priority to US11/628,458 priority patent/US7700613B2/en
Priority to HR20110718T priority patent/HRP20110718T1/hr
Priority to SI200531393T priority patent/SI1773451T1/sl
Priority to MXPA06014162A priority patent/MXPA06014162A/es
Priority to DK05761294.7T priority patent/DK1773451T3/da
Priority to CA2565213A priority patent/CA2565213C/en
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority to BRPI0511931-6A priority patent/BRPI0511931A/pt
Priority to JP2007526712A priority patent/JP2008501785A/ja
Priority to KR1020067027912A priority patent/KR101221640B1/ko
Priority to EP05761294A priority patent/EP1773451B1/en
Publication of WO2005120643A2 publication Critical patent/WO2005120643A2/en
Publication of WO2005120643A3 publication Critical patent/WO2005120643A3/en
Anticipated expiration legal-status Critical
Publication of WO2005120643A8 publication Critical patent/WO2005120643A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the use of 7-terbutoxy- iminomethylcamptothecin for the preparation of a medicament with anticancer activity, particularly against uterine tumours.
  • Anticancer chemotherapy agents are the drugs with the most restrictive therapeutic window. In fact, since their cytotoxic activity is non- selective, they can indiscriminately damage all the cells of the body with which they come into contact.
  • uterine cancers the term including both cervical and endometrial carcinoma, have become the most frequent pelvic cancers in women.
  • Surgery is the treatment of choice in most patients.
  • the use of chemotherapy is generally confined to the treatment of metastatic or advanced disease.
  • the chemotherapeutic agents commonly prescribed for the treatment of uterine cancers are characterised by a fairly low positive response level, ranging typically from 20% to 35%. There is therefore still a perceived need to identify an anticancer drug capable of yielding a higher positive response rate and at the same time presenting fewer side effects or at least to a more tolerable extent.
  • CPT184 or ST 1481 or gimatecan 7-terbutoxyiminomethylcamptothecin is an orally active camptothecin derivative and is described in European Patent EP 1 044 977, where its activity on the non-small-cell lung cancer cell line is specified, and uterine cancers are not mentioned.
  • gimatecan is also active in uterine tumours, particularly of the endometrium and neck of the womb. Therefore, one subject of the present invention is the use of 7-t- butoxyiminomethylcamptothecin, hereinafter also referred to as gimatecan, for the preparation of a medicament for the treatment of uterine cancers, particularly of the endometrium and neck of the womb.
  • Another object of the present invention is a method for treating a patient suffering from uterine neoplasm comprising administering to said patient an effective amount of 7-t-butoxyiminomethylcamptothe-cin.
  • the medicament which is the subject of the present invention will take the form of a pharmaceutical composition, such as is described, for example, in the above-mentioned European Patent.
  • the pharmaceutical form will be suitable for oral administration.
  • the active ingredient will be incorporated in liposomal formulations, such as are described, for example, in international patent application PCT/ITOO/00137, or in some other form that allows its administration via the parenteral route.
  • Gimatecan is a new anticancer compound that has shown a high therapeutic index in preclinical trials in vivo. Moreover, gimatecan is characterised by an anticancer activity that is maintained with different administration regimens, both intermittent and prolonged.
  • gimatecan was administered as a single therapeutic agent with different administration regimens.
  • the patients studied were affected by advanced cancers for which curative or standard therapy was no longer indicated.
  • the aim of the study was to assess the tolerability of the treatment with gimatecan
  • gimatecan produced a number of lasting objective clinical responses.
  • Particularly worthy of mention are the responses of a number of patients with uterine cancers, both of the cervix and the endometrium, including forms which had received substantial previous treatments and presented metastatic disease.
  • These clinical responses were defined as partial responses, that is to say they presented a more than 30% reduction of the tumour lesion or lesions, as assessed by means of diagnostic imagining techniques such as computed tomography.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/IT2005/000320 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms Ceased WO2005120643A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2565213A CA2565213C (en) 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
AT05761294T ATE521351T1 (de) 2004-06-11 2005-06-08 Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren
BRPI0511931-6A BRPI0511931A (pt) 2004-06-11 2005-06-08 uso de 7-t-butoxiiminometilcamptotecina para a preparação de um medicamento para o tratamento de neoplasmas uterinos
HR20110718T HRP20110718T1 (hr) 2004-06-11 2005-06-08 UPOTREBA 7-t-BUTOKSIIMINOMETILKAMPTOTECINA U LIJEČENJU NOVOTVORINA MATERNICE
SI200531393T SI1773451T1 (sl) 2004-06-11 2005-06-08 Uporaba 7-t-butoksiiminometilkamptotecina za zdravljenje uterinih neoplazem
MXPA06014162A MXPA06014162A (es) 2004-06-11 2005-06-08 Uso de 7-t-butoximinometilcamptotecina para tratar neoplasmas uterinos.
DK05761294.7T DK1773451T3 (da) 2004-06-11 2005-06-08 Anvendelse af 7-t-butoxyiminomethylcamptothecin til behandling af uterine neoplasmer
PL05761294T PL1773451T3 (pl) 2004-06-11 2005-06-08 Zastosowanie 7-t-butoksyiminometylokamptotecyny do leczenia nowotworów macicy
US11/628,458 US7700613B2 (en) 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
AU2005251573A AU2005251573B2 (en) 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms
JP2007526712A JP2008501785A (ja) 2004-06-11 2005-06-08 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
KR1020067027912A KR101221640B1 (ko) 2004-06-11 2005-06-08 자궁 종양 치료용 약제의 제조를 위한7-티-부톡시이미노메틸캄토테신의 용도
EP05761294A EP1773451B1 (en) 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2004A000288 2004-06-11
IT000288A ITRM20040288A1 (it) 2004-06-11 2004-06-11 Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.

Publications (3)

Publication Number Publication Date
WO2005120643A2 true WO2005120643A2 (en) 2005-12-22
WO2005120643A3 WO2005120643A3 (en) 2006-03-30
WO2005120643A8 WO2005120643A8 (en) 2006-12-14

Family

ID=34979678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2005/000320 Ceased WO2005120643A2 (en) 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms

Country Status (23)

Country Link
US (1) US7700613B2 (enExample)
EP (1) EP1773451B1 (enExample)
JP (2) JP2008501785A (enExample)
KR (1) KR101221640B1 (enExample)
CN (2) CN1953784A (enExample)
AR (1) AR049220A1 (enExample)
AT (1) ATE521351T1 (enExample)
AU (1) AU2005251573B2 (enExample)
BR (1) BRPI0511931A (enExample)
CA (1) CA2565213C (enExample)
CY (1) CY1112032T1 (enExample)
DK (1) DK1773451T3 (enExample)
ES (1) ES2372056T3 (enExample)
HK (1) HK1205951A1 (enExample)
HR (1) HRP20110718T1 (enExample)
IT (1) ITRM20040288A1 (enExample)
MX (1) MXPA06014162A (enExample)
PL (1) PL1773451T3 (enExample)
PT (1) PT1773451E (enExample)
RS (1) RS52038B (enExample)
SI (1) SI1773451T1 (enExample)
TW (1) TWI351283B (enExample)
WO (1) WO2005120643A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017513A3 (en) * 2005-08-10 2007-04-05 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
WO2008094959A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757514B1 (fr) * 1996-12-20 1999-02-12 Sod Conseils Rech Applic Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE69635560T2 (de) * 1995-06-21 2006-08-17 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
UA57757C2 (uk) * 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
DK1044977T3 (da) 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
WO2003043584A2 (en) 2001-11-20 2003-05-30 University Of Kentucky Research Foundation Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017513A3 (en) * 2005-08-10 2007-04-05 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
WO2008094959A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative

Also Published As

Publication number Publication date
TWI351283B (en) 2011-11-01
CN1953784A (zh) 2007-04-25
SI1773451T1 (sl) 2012-01-31
JP2008501785A (ja) 2008-01-24
ES2372056T3 (es) 2012-01-13
WO2005120643A8 (en) 2006-12-14
BRPI0511931A (pt) 2008-01-22
CA2565213C (en) 2012-08-07
CA2565213A1 (en) 2005-12-22
AU2005251573B2 (en) 2010-04-15
CY1112032T1 (el) 2015-11-04
ITRM20040288A1 (it) 2004-09-11
PT1773451E (pt) 2011-11-02
JP2014231518A (ja) 2014-12-11
AR049220A1 (es) 2006-07-05
WO2005120643A3 (en) 2006-03-30
CN104352496A (zh) 2015-02-18
AU2005251573A1 (en) 2005-12-22
US7700613B2 (en) 2010-04-20
DK1773451T3 (da) 2011-11-28
KR101221640B1 (ko) 2013-01-14
MXPA06014162A (es) 2007-03-07
EP1773451A2 (en) 2007-04-18
EP1773451B1 (en) 2011-08-24
US20080020030A1 (en) 2008-01-24
RS52038B (sr) 2012-04-30
HRP20110718T1 (hr) 2011-12-31
KR20070030246A (ko) 2007-03-15
TW200605891A (en) 2006-02-16
ATE521351T1 (de) 2011-09-15
HK1205951A1 (en) 2015-12-31
PL1773451T3 (pl) 2012-01-31

Similar Documents

Publication Publication Date Title
Kudelka et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
US20220072011A1 (en) Treatments of accumulated fat with deoxycholic acid and salts thereof
Fischer et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat
US20070010550A1 (en) Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia
TW201919618A (zh) 用於治療肉瘤的化合物
CN112638378A (zh) 用于根除幽门螺杆菌的组合物
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2023522415A5 (enExample)
JP2024539476A5 (enExample)
CN109862895A (zh) 结节性痒疹的治疗
US7700613B2 (en) Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
US20230193219A1 (en) Superoxide dismutase compositions and methods
KR20200066664A (ko) 세균 감염증을 치료하는 방법
JP4306837B2 (ja) スクラルファート含有局所投与用医薬組成物
HK1104002A (en) Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms
JPH10511108A (ja) テモゾロミドおよびシスプラチンを含む進行ガンに対する組み合わせ治療
ES2668943T3 (es) Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz
WO2026100645A1 (en) Methods for treating vasomotor symptoms in breast cancer patients with fezolinetant
Jeffcoate et al. Ethinyl oestradiol
US20230295585A1 (en) Superoxide dismutase compositions and methods
CN108853007B (zh) 一种治疗功能性子宫出血的凝胶制剂及其用途
Sudarsa et al. A case of pemphigus vulgaris in a patient with abdominal tumor as collaborative disease
US20020123480A1 (en) Methods and compositions utilizing 2'-5' oligoadenylates in the treatment of disorders of cell proliferation
Israel et al. Omalizumab does not induce thrombocytopenia in the treatment of asthma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2565213

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580015728.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 3617/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/014162

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2005251573

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007526712

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005761294

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067027912

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005251573

Country of ref document: AU

Date of ref document: 20050608

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005251573

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067027912

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005761294

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11628458

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0511931

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11628458

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P-2011/0434

Country of ref document: RS